Octagon Capital Advisors LP Purchases Shares of 414,000 Structure Therapeutics Inc. (NASDAQ:GPCR)

Octagon Capital Advisors LP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 414,000 shares of the company’s stock, valued at approximately $16,875,000. Structure Therapeutics comprises 2.7% of Octagon Capital Advisors LP’s investment portfolio, making the stock its 10th largest holding.

Other institutional investors and hedge funds also recently modified their holdings of the company. Parkman Healthcare Partners LLC increased its holdings in shares of Structure Therapeutics by 28.9% during the 4th quarter. Parkman Healthcare Partners LLC now owns 38,678 shares of the company’s stock worth $1,577,000 after acquiring an additional 8,678 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new position in Structure Therapeutics during the fourth quarter worth $12,929,000. Brandywine Managers LLC increased its holdings in shares of Structure Therapeutics by 9.2% in the fourth quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock valued at $489,000 after purchasing an additional 1,007 shares during the last quarter. Boxer Capital LLC bought a new position in shares of Structure Therapeutics in the fourth quarter valued at about $16,304,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth about $163,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $48.17 on Friday. The company has a market cap of $2.25 billion and a price-to-earnings ratio of -62.56. Structure Therapeutics Inc. has a fifty-two week low of $25.57 and a fifty-two week high of $75.02. The stock has a fifty day moving average price of $40.69 and a 200-day moving average price of $42.80.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.02. Research analysts predict that Structure Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. BMO Capital Markets upped their target price on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 3rd. Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Friday, May 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $85.25.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.